Inovelon® (Rufinamide) Oral Suspension Formulation Launched in Portugal

Inovelon® (Rufinamide) Oral SuspensionInovelon® (Rufinamide) Oral Suspension Formulation Launched in Portugal PR Newswire HATFIELD, England, December 17, 2013 PRESS RELEASE NOT FOR U.S. MEDIA Child friendly formulation will help treatment of orphan syndrome LGS, a severe form of childhood epilepsy ®Inovelon (rufinamide) oral suspension for adjunctive (add-on) treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in children [1]four years and older has launched in Portugal. The new formulation of the orphan drug has been developed as a child friendly drinkable liquid to aid the administration of treatment. "The availability of the suspension formulation of rufinamide in Portugal will potentially help young patients adhere better to treatment, which may help improve outcomes in the management of this severe and highly debilitating condition," commented Dr. Pedro Cabral, Neuropaediatrician, Director Clinico do CADIn, Cascais, Portugal. LGS is one of the most severe forms of childhood epilepsy and accounts [2]for 5% of epilepsy in children, with the peak of onset at between ages [3]three and five. LGS is characterised by multiple daily seizures and [4]people with the condition can have up to 70 seizures a day. Most children with LGS also experience developmental problems leading to [5]impaired intellectual function and behavioural issues.